Supramolecular networks featuring diverse array of noncovalent interactions in crystals of hydrazinylidene-benzothiazinediones: X-ray crystallographic, DFT and biochemical analysis


Zaib S., Munir R., Khan I., Javid N., Huma R., Mustafa U., ...More

Journal of Molecular Structure, vol.1306, 2024 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 1306
  • Publication Date: 2024
  • Doi Number: 10.1016/j.molstruc.2024.137840
  • Journal Name: Journal of Molecular Structure
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, Chimica, Compendex, INSPEC
  • Keywords: Benzothiazine, C-H⋯Cl contacts, DFT calculations, Hydrogen bonding, Malone type III interactions, Noncovalent interactions, QTAIM/NCI analysis, Urease inhibition
  • Hacettepe University Affiliated: Yes

Abstract

The intricate role of noncovalent interactions in numerous fields including chemistry, biology, catalysis, material science, and medicinal chemistry provides a continuous impetus towards the discovery of new synthons that stabilize the supramolecular architectures. In this regard, the current work presents a series of five hydrazinylidene-benzothiazinedione derivatives encompassing a wide plethora of noncovalent interactions. Despite the configurational similarity of their hydrazinylidene-benzothiazinedione component, the five crystallographic packing arrangements of 7a–c and 9a,b are unique. The principal intermolecular interactions are C–H⋯O hydrogen bonds and weak C–H···π interactions (Malone Type III). Inversion dimers based on C–H⋯Cl interactions form for 7b while C–H⋯N and C–H⋯S interactions in 9a were also observed. Furthermore, the energetic properties of the supramolecular dimers, centrosymmetric (antiparallel oriented) arrangements in 7a and 7b while parallel oriented arrangements in 9a and 9b have been examined using a combined QTAIM/NCI plot methods. The medicinal chemistry potential against urease enzyme revealed compound 9b as the lead inhibitor with strong efficacy (IC50 = 0.92 ± 0.03 µM). In vitro results were complemented with molecular docking revelations where several key interactions were observed between the potent ligand and active site amino acids. ADMET profile also described compounds 7b and 9b as the best molecules with promising druglike profile.